Read scientific publications, watch presentations and talks, and learn about new initiatives here.
The Evolution of a Multi-Biomarker Class Approach to Multi-Cancer Early Detection Testing
Performance of a multi-analyte, multi-cancer early detection (MCED) blood test in a prospectively-collected cohort
DETECT-A participants with pre-malignant conditions diagnosed consequent to an MCED test
DETECT-A participants with pre-malignant conditions diagnosed consequent to an MCED test
Performance of a multi-analyte, multi-cancer early detection (MCED) blood test in a prospectively-collected cohort
See our advancements presented at the European Society of Medical Oncology (ESMO) Congress 2023
Pioneering a Paradigm Shift in Cancer Screening: The Era of Multi-cancer Early Detection Testing
The Evolution of a Multi-Biomarker Class Approach to Multi-Cancer Early Detection Testing
Long-term clinical outcomes of cancers diagnosed following detection by a blood-based MCED test
Cancer Moonshot
Congress bill H.R. 2407
MCED Consortium
The Cancerguard™ test is under development. The features above describe current development goals. It has not been cleared or approved by the US Food and Drug Administration or any other national regulatory authority.
